Lack of reduction in body fat after treatment with insulin-like growth factor-I in two children with growth hormone gene deletions
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Two patients with growth hormone (GH) gene deletions were treated with recombinant insulin-like growth factor-I (IGF-I) (80–240 (μg/kg/ day) and the effects on bone mass and body composition were compared to administration of GH (0.075 U/kg/day) to 8 patients with idiopathic GH deficiency. Bone mass and body composition were measured by dual photon X-ray absorptiometry (DEXA) before and 3 and 6 months after treatment with GH or IGF-I. Similar increases in growth velocities were observed after GH and IGF-I treatment. Treatment with GH resulted in prompt and significant reduction in body fat percentage (basal, 3 and 6 months: 22±10, 17±9, and 16±9%) whereas body fat percentage remained unchanged after IGF-I therapy (basal, 3 and 6 months: 49, 52 and 48% in patient 1 and 45, 42 and 43% in patient 2, respectively). Fat percentage remained elevated after 18 months of IGF-I treatment in patients 1 (51%) and 2 (44%), respectively. Lean mass and bone mineral content increased with GH and IGF-I therapies. We conclude that reduction of body fat measured by DEXA, observed after administration of GH but not after IGF-I treatment in these children with GH deficiency, suggests that the GH effect on body fat mass is not mediated by circulating IGF-I.
- Richelsen B. Action of growth hormone in adipose tissue. Horm. Res. 1997, 48 (Suppl. 5): 105–110. CrossRef
- Rosen T., Bengtsson B.A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336: 285–288. CrossRef
- Boot A.M., Engels M.A.M.J., Boerma G.J.M., Krenning E.P., de Muinck Keizer-Schrama S.M.P.F. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J. Clin. Endocrinol. Metab. 1997, 82: 2423–2428.
- Degerblad M., Elgingy N., Hall K., Sjöberg H.E., Thoren M. Potent effect of recombinant human growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocr. (Copenh) 1992, 126: 387–393.
- Laron Z., Klinger B. Body fat in Laron syndrome patients: effect of insulinlike growth factor I treatment. Horm. Res. 1993, 40: 16–22. CrossRef
- Guevara-Aguirre J., Rosenbloom A.L., Vasconez O., Martinez V., Gargosky S.E., Allen L., Rosenfeld R.G. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: Comparison of two dosage levels and to GH-treated GH deficiency. J. Clin. Endocrinol. Metab. 1997, 82: 629–633.
- Underwood L.E., Backeljauw P., Duncan V., GHIS Collaborative Group. Effects of insulin-like growth factor I treatment on statural growth, body composition and phenotype of children with growth hormone insensitivity syndrome. Acta Paediatr. Scand. 1999, Suppl. 428: 182–184. CrossRef
- Kamijo T., Phillips J.A. III Detection of molecular heterogeneity in GH-1 gene deletions by analysis of polymerase chain reaction amplification products. J. Clin. Endocrinol. Metab. 1992, 74: 786–789. CrossRef
- Arnhold I.J.P., Oliveira S.B., Osorio M.G.F., Mendonca B.B. Insulin-like growth factor-I treatment in two children with growth hormone gene deletions. J. Pediatr. Endocrinol. Metab. 1999, 12: 499–506. CrossRef
- Boot A.M., Bouquet J., de Ridder M.A.J., Krenning E.P., de Muinck Keizer-Schrama S.M.P.F. Determinants of body composition measured by dualenergy X-ray absorptiometry in Dutch children and adolescents. Am. J. Clin. Nutr. 1997, 66: 232–238.
- Carrilho A.J.F., Medina W.L., Nakandakare E.R., Quintão E.C.R. Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine. Clin. Pharmacol. Ther. 1997, 62: 82–88. CrossRef
- Osorio M.G.F., Bianco A.C., Estefan V., Segura T.C., Arnhold I.J.P., Nicolau W., Mendonca B.B. Body composition and bone mass of children with hypopituitarism following six months of human growth hormone therapy. Arq. Bras. Endocrinol. Metabol. 1998, 42: 357–362.
- Ranke M.B., Savage M.O., Chatelain P.G., Preece M.A., Rosenfeld R.G., Blum M.F., Wilton P. Insulin-like growth factor I improves height in growth hormone insensitivity: Two years results. Horm. Res. 1995, 44: 253–264. CrossRef
- Backeljauw P.F., Underwood L.E., GHIS Collaborative Group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - A clinical research center study. J. Clin. Endocrinol. Metab. 1996, 81: 3312–3317.
- Klinger B., Laron Z. Three year treatment of children with Laron syndrome. J. Pediatr. Endocrinol. Metab. 1995, 8: 149–158. CrossRef
- Woods K.A., Camacho-Hübner C., Savage M.O., Clark A.J.L. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. New Engl. J. Med. 1996, 335: 1363–1367. CrossRef
- Heinrichs C., Vis H.L., Bergmann P., Wilton P., Bourguignon J.P. Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome. Clin. Endocrinol. 1993, 38: 647–651. CrossRef
- Rudling M., Olivecrona H., Eggertsen G., Angelin B. Regulation of rat hepatic low density lipoprotein receptors–in vivo stimulation by growth hormone is not mediated by insulin-like growth factor I. J. Clin. Invest. 1996, 97: 292–299. CrossRef
- Rudling M., Norstedt G., Olivecrona H., Reihnér E., Gustafsson J.-A., Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc. Natl. Acad. Sci. USA. 1992, 89: 6983–6987. CrossRef
- Lack of reduction in body fat after treatment with insulin-like growth factor-I in two children with growth hormone gene deletions
Journal of Endocrinological Investigation
Volume 23, Issue 4 , pp 258-262
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- IGF-I treatment
- body composition
- GH deficiency
- GH gene deletions
- body fat
- Industry Sectors
- Author Affiliations
- 110. Unidade de Endocrinologia do Desenvolvimento, Hospital das Clinicas da Faculdade de Medicina da USP, Caixa Postal 3671, CEP 01060-970, São Paulo, Brazil
- 210. Laboratório de Lípides, Divisão de Endocrinologia, Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil
- 310. Departmento de Fisiologia e Biofísica, ICB, Universidade de São Paulo, São Paulo, Brazil